[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"back-pain\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:back-pain":30},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,41,0,25,[9,45,79,107,140,175,196,223,251,272,301,343,367,391,414,446,470,492,520,556,576,599,625,651,677],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100643910","phase-1-intradiscal-rhgdf-6-for-the-treatment-of-lumbar-disc-degeneration-100643910",false,"NCT07668466","Intradiscal rhGDF-6 for the Treatment of Lumbar Disc Degeneration","A Phase I\u002FII, Open-label, Single Administration Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of Intradiscal rhGDF-6 for the Treatment of Lumbar Disc Degeneration","CBT005","Inclusion Criteria\n\n1. Persistent low back pain, with at least 3 months of non-surgical therapy, at one symptomatic disc or two symptomatic lumbar disc levels (from L2 to S1).\n2. MRI scans show Pfirrmann disc degeneration grade 2 to 4 or High Intensity Zone (HIZ) signal change with or without Modic endplate changes.\n3. Symptoms are a fair bit or a lot bothersome, which require medication or other types of treatments or very disrupting (in response to question\\*).\n4. Preoperative Oswestry Disability Index (ODI) score greater than or equal to 30%\n5. Visual Analog Score for back pain ≥40 mm.\n6. Any gender, 18 years of age or older\n7. Clinician diagnosed discogenic pain\n8. A signed HREC-approved Informed Consent Form\n9. Able to meet the protocol follow-up schedule and activities\n10. Females of childbearing potential must have a negative urine\u002Fserum pregnancy test at screening (Baseline Visit) and on the day of administration prior to injection \\*Question defined in full protocol\n\nExclusion Criteria\n\n1. People unable to have an MRI\n2. Abnormal neurological exam at baseline (e.g., chronic radiculopathy)\n3. Active radicular pain due to anatomical compression such as stenosis or disc herniation\n4. Symptomatic facet joints and\u002For severe facet degeneration at the index level or adjacent segments\n5. Symptomatic Sacro-iliac joint\n6. MRI findings demonstrate any of the following: Suspected disc appears normal or \\>50% decrease in disc height or Presence of symptomatic osteophytes\n7. Any prior lumbar spinal surgeries at suspected symptomatic level; prior surgery at the adjacent levels is acceptable including fusion or arthroplasty, provided the said adjacent level is not independently symptomatic.\n8. Presence of spondylolisthesis (anterolisthesis, retrolisthesis is acceptable)\n9. Symptomatic disc degeneration at more than 2 lumbar levels (multi-level disc degeneration based on MRI findings is acceptable with up to two symptomatic level. Only the symptomatic levels will be treated)\n10. Evidence of active infection\n11. Immunosuppressive therapy within 3 months prior to investigational product administration\n12. Either continuous or cumulative use of more than 2 months use in the past 6 months of an oral or systemic steroid. Inhaled steroids are acceptable\n13. Tumor in the spine\n14. People with any current and previous cancer. An exemption to this is previous BCCs which have been successfully removed.\n15. Non-contained herniated nucleus pulposus\n16. Any prior intradiscal therapies (chemonucleolysis, IDET, intradiscal steroid injection) at the same level being treated, other than rhGDF-6.\n17. Any non-intradiscal steroid injection less than 2 months prior to administration. Does not include isolated joint injections outside the lumbar region.\n18. Nerve block injection less than 2 months prior to injection of study medication.\n19. Known autoimmune disease\n20. Type 1 Insulin-dependent diabetes mellitus (Type II, non-insulin dependent diabetes mellitus is allowed)\n21. Pregnant or lactating, or wishes to become pregnant within the first 12 months of the study\n22. Involved in pending litigation of the spine (including workers compensation cases)\n23. Demonstrates signs of non-organic pain (e.g., Waddell's Signs)\n24. Based on clinical history, physical examination and participant presentation, participant has, or is suspected to have, a history of alcohol and\u002For drug abuse that would preclude participants from providing adequate consent and\u002For complying with study requirements\n25. Prisoner\n26. Morbid Obesity, defined as Body Mass Index (BMI) ≥40\n27. Life expectancy less than 2 years\n28. Any significant psychological disturbance past or present, that could impair the consent process or ability to complete participant self-report questionnaires\n29. Any reason not cited above that, in the opinion of the Principal Investigator, would pose a risk to either the participant or to the integrity of the clinical trial","ALL","18 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE1","PHASE2","The goal of this clinical trial is to find out if a new medicine can help people who have long-lasting back pain caused by damaged spinal discs. The study will also check if the medicine is safe to use.\n\nThe main questions this study aims to answer are:\n\nIs the medicine safe, and what amount works best? Can it reduce long-term back pain?\n\nResearchers will test a medicine called CBT005, which contains a healing protein, by injecting it into the spinal discs. They will watch closely to see how people respond to the treatment.\n\nParticipants will:\n\nReceive one study injection into the spinal disc Visit the clinic in person during the first 12 months for checkups Receive phone calls at 24 and 36 months to see how they are doing Still be able to get other pain treatments in the future, including surgery, if needed",[29,30],"Disc Degenerative Disease","Back Pain",[30],"NOT_YET_RECRUITING","2026-06-21",{"date":35,"type":36},"2026-06-25","ACTUAL",{"date":38,"type":22},"2026-07-04",{"date":40,"type":22},"2030-12-01",{"name":42,"class":43},"Cartago Biotech Pty Ltd","INDUSTRY",1,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":23,"phases":55,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":78},"100643477","phase-4-erector-spinae-plane-block-versus-trigger-point-injection-for-chronic-thoracic-myofascial-pain-100643477","NCT07632820","Erector Spinae Plane Block Versus Trigger Point Injection for Chronic Thoracic Myofascial Pain","Ultrasound-guided Erector Spinae Plane (ESP) Block Versus Trigger Point Injection (TPI) for Chronic Thoracic Myofascial Pain: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults aged 18-80 years\n* Chronic thoracic myofascial pain lasting at least three months\n* Pain intensity of ≥4 on 11-point NRS\n* At least two of three following conditions: Focal thoracic paraspinal pain, palpable taut band, referred pain pattern with palpation\n\nExclusion Criteria:\n\n* Thoracic radiculopathy\n* Cervical myelopathy with neurological deficit\n* Prior cervicothoracic spine surgery\n* Pregnancy or lactation\n* Contraindication to local anesthetic\n* Active malignancy\n* Fibromyalgia\n* BMI \\>40 kg\u002Fm2\n* Workers' compensation or active litigation related to thoracic pain\n* Acute herpes zoster or history of postherpetic neuralgia involving thoracic dermatomes\n* Current opioid use \\>50 morphine milligram equivalents daily\n* Severe psychiatric or cognitive disorders, specifically history of schizophrenia, chronic psychotic disorders, dementia\n* History of substance use disorder\n* Inability to provide informed consent","80 Years",{"count":54,"type":22},76,[56],"PHASE4","Chronic thoracic (mid-back) pain can be difficult to treat, and there is limited evidence to guide the use of injection therapies for pain arising from muscles and surrounding soft tissues. Two commonly used treatments are trigger point injections (TPI) and erector spinae plane (ESP) blocks, but no studies have directly compared their effectiveness for chronic thoracic myofascial pain. The purpose of this study is to compare pain relief, physical function, emotional well-being, patient satisfaction, and safety following treatment with either an ESP block or TPI. Participants will be randomly assigned to receive one of the two treatments. Researchers will follow participants for up to 12 weeks after the procedure and collect information through questionnaires and pain assessments.",[30],[60,61,62,63,64,65,66],"thoracic back pain","myofascial pain","thoracic myofascial pain","Trigger point injection","Erector spinae plane block","TPI","ESP block","RECRUITING","2026-06-03",{"date":70,"type":36},"2026-06-08",{"date":72,"type":22},"2026-08-01",{"date":74,"type":22},"2029-08-30",{"name":76,"class":77},"Mayo Clinic","OTHER",5,{"id":80,"slug":81,"hasResults":12,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":23,"phases":88,"briefSummary":90,"conditions":91,"keywords":95,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":102,"completionDateStruct":103,"leadSponsor":105,"locationsCount":44},"100643353","efficacy-of-the-erector-spinae-plane-block-for-persistent-back-pain-in-patients-with-ankylosing-spondylitis-100643353","NCT07633730","Efficacy of the Erector Spinae Plane Block for Persistent Back Pain in Patients With Ankylosing Spondylitis","Inclusion Criteria:\n\n* Age between 18 and 65 years\n* Diagnosis of ankylosing spondylitis according to the Modified New York Criteria\n* Patients receiving ongoing treatment with controlled disease activity but persistent back pain\n* Willingness to participate in the study\n\nExclusion Criteria:\n\n* Body mass index (BMI) greater than 35 kg\u002Fm²\n* History of thoracic surgery\n* Intellectual disability or mental retardation\n* Presence of major psychiatric comorbidity\n* Congenital spinal anomaly\n* Pregnancy\n* History of bleeding diathesis\n* Presence of active local and\u002For systemic infection\n* Known allergy to the medications to be injected\n* Hemodynamic instability\n* Active phase of the disease (elevated acute phase reactants, active arthritis findings, etc.)","65 Years",{"count":87,"type":22},15,[89],"NA","Despite adequate control of disease activity with standard medical therapies, there remains an ongoing need for complementary and interventional approaches for the management of persistent back pain in patients with ankylosing spondylitis. Although the erector spinae plane block has been described in the literature as a safe and effective analgesic intervention for chronic back pain in various patient populations, to the best of our knowledge, no clinical study has specifically evaluated its use for persistent back pain in patients with ankylosing spondylitis receiving medical treatment. Therefore, the present study aims to evaluate the effects of erector spinae plane block on pain severity and clinical outcomes in patients with ankylosing spondylitis whose disease activity is controlled under treatment but who continue to experience persistent back pain.",[92,30,93,94],"Ankylosing Spondylitis (AS)","ESPB","Regional Anesthesia",[93,96,30,97,98,99],"Erector Spinae Plane Block","Ankylosing Spondylitis","Persistent back pain","Regional anesthesia","2026-06-02",{"date":70,"type":36},{"date":100,"type":36},{"date":104,"type":22},"2027-06-02",{"name":106,"class":77},"Marmara University",{"id":108,"slug":109,"hasResults":12,"nctId":110,"briefTitle":111,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":113,"sex":18,"minAge":114,"maxAge":85,"enrollmentInfo":115,"targetDuration":4,"studyType":23,"phases":117,"briefSummary":119,"conditions":120,"keywords":127,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":44},"100437952","early-phase-1-brain-mechanisms-supporting-cannabis-induced-pain-relief-100437952","NCT04982965","Brain Mechanisms Supporting Cannabis-induced Pain Relief","Inclusion Criteria:\n\n* Between 21-65 years old\n* Currently 30 days cannabis free\n* Lower back pain for three months or more\n* Are not taking opioids\n* If female and of a child bearing potential age, are not pregnant or nursing mothers\n* Do not have mental or neurological conditions inhibiting sensory\u002Fmotor functions\n* Do not have a lifetime history of dependence on cannabis\n* Do not have a lifetime history of DSM-IV schizophrenia, bipolar disorder, panic disorder, or psychosis\n* Prior THC-containing cannabis experience within the past two years\n* Agrees not to use cannabis outside of the study during participation in the study\n* Agrees not to use opioids or barbiturates during participation in the study\n* Agrees not to drive a motor vehicle within 4 hours following last use of inhaled cannabis during participation in the study\n\nExclusion Criteria:\n\n* Active pulmonary disease\n* Allergy or past adverse effects or negative past experiences from cannabis\n* Positive urine drug test for THC, barbiturates, opioids, oxycodone, or methadone\n* Any significant illness, including cardiovascular disease, diabetes, renal and liver disease.\n* Any current or history of an immunocompromising disease or condition (such as lupus, psoriasis, multiple sclerosis, etc.)\n* Any current or history of neurologic conditions, including Parkinson disease, dementia, cognitive impairment, history of seizure disorder, and history of traumatic brain injury\u002Fhead injury\n* Any current major psychiatric illness, such as bipolar disorder, major depression, psychosis, substance use disorder, or schizophrenia\n* Any current or history of suicidal ideation or attempt\n* Overt sensitivity to thermal stimulation\n* Resting blood pressure \\> 140\u002F90\n* Resting heart rate \\> 100 beats\u002Fminute\n* Prisoner\n* Institutionalized\n* Claustrophobia\n* MRI contraindications\n* Participation in any new (within 2 weeks prior or any time after enrollment) pain management procedures during the study period\n* Known history of vasovagal fainting, syncope, or severe adverse reactions associated with blood draws or needle procedures",true,"21 Years",{"count":116,"type":22},100,[118],"EARLY_PHASE1","Chronic low back pain is a common and disabling condition that affects millions of people in the United States. Many people with chronic low back pain do not get enough relief from current treatments. Cannabis may help reduce pain, but researchers do not fully understand how it affects the brain in people with chronic pain. The purpose of this study is to examine how inhaled cannabis changes brain activity and reduces pain in people with chronic low back pain. Results from this study may help researchers better understand how cannabis works for pain and support the development of improved pain treatments.",[121,122,123,124,125,126,30],"Sciatica","Lumbar Radiculopathy","Lower Back Pain","Degenerative Disc Disease","Chronic Low-back Pain (cLBP)","Chronic Low Back and Leg Pain",[128,129,130,131],"Cannabis","Vaporized cannabis","THC","chronic low back pain","2026-05-30",{"date":68,"type":36},{"date":135,"type":36},"2021-05-07",{"date":137,"type":22},"2027-03-15",{"name":139,"class":77},"University of California, San Diego",{"id":141,"slug":142,"hasResults":12,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":146,"eligibilityCriteria":147,"healthyVolunteers":113,"sex":148,"minAge":19,"maxAge":149,"enrollmentInfo":150,"targetDuration":4,"studyType":23,"phases":152,"briefSummary":153,"conditions":154,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":44},"100640820","phase-1-hormones-outcomes-and-pain-pathways-in-exercise-study-100640820","NCT07579182","Hormones, Outcomes, and Pain Pathways in Exercise Study","Mechanical and Non-mechanical Contributions to Chronic Neck, Shoulder, Arm, and Back Pain in Full-busted Women","HOPE","Inclusion Criteria:\n\n1. Able to provide informed consent\n2. Age of 18 to 60 years\n3. Assigned female sex at birth\n4. Right-handed by self-declaration\n5. Willing to participate in one online testing session and up to four in-person testing sessions\n6. Bra band size between 32-40\"\n7. International Physical Activity Questionnaire - Short Form (IPAQ-SF) score of 2 or higher\n8. An answer of \"NO\" to any item of the general health questions of the PARQ+\n9. No history of surgery to the: back, neck, or shoulders or joint replacement\n10. No history of implanted pacemakers or other stimulation devices\n11. No history of spinal cord injury (SCI)\n\nExclusion Criteria:\n\n1. Inability to provide informed consent\n2. Age 17 years old or younger or 61 years or older\n3. Assigned male sex at birth\n4. Left-handed by self-declaration\n5. Not willing to participate in one online testing session and up to four in-person testing sessions\n6. Bra band size greater than 40\" or less than 32\"\n7. IPAQ-SF score of 1 or lower\n8. An answer of \"YES\" to any item of the general health questions of the PARQ+\n9. History of limb amputation (upper or lower extremity)\n10. Presence of open pressure sores on the upper or lower extremities\n11. Currently pregnant or lactating\u002Fbreastfeeding\n12. History of surgery to the: back, neck, or shoulders or joint replacement\n13. History of breast cancer and\u002For mastectomy\n14. History of implanted pacemakers or other stimulation devices\n15. History of spinal cord injury (SCI)\n16. History of joint disease including osteoarthritis and\u002For Rheumatoid Arthritis\n17. History of the following neurological diseases: Cerebrovascular accident (CVA, stroke), Alzheimer's Disease (AD), Dementia (of any form), Huntington's Disease, Traumatic Brain Injury (TBI), Spinal cord injury (SCI), Multiple Sclerosis (MS), Parkinson's Disease (PD), Polio, Paraproteinaemic Demyelinating Neuropathy (PDN) and\u002For Monoclonal Gammopathy of Undetermined Significance (MGUS), Myasthenia Gravis, Muscular Dystrophy, Guillain-Barré Syndrome, Scoliosis, Charcot-Marie-Tooth Disorder or other hereditary neuropathies\n\nAdditional Inclusion Criteria for Intervention Group:\n\na. Self-declared breast size of D-I cup (US sizes: D, E, F, G, H)\n\nAdditional Inclusion Criteria for the Control Group:\n\na. Self-declared breast size of A-C cup (US sizes: AA, A, B, C)","FEMALE","60 Years",{"count":151,"type":22},140,[25],"The goal of the proposed project is to evaluate a mechanical intervention (sports bras designed specifically for full busted women) to alleviate neck, shoulder, arm, and back pain in full-busted women and investigate the contribution of non-mechanical pathways associated with this type of pain in women. Specifically, the investigators will investigate how sex-hormones, inflammation, and remapping of specific regions of the brain contribute to the manifestation of neck, shoulder, arm, and back pain in full-busted women across the lifespan.",[155,156,30,157,158,159,160,161,162,163,164,165,166],"Breast Pain","Mastalgia","Back Pain, Low","Neck Pain","Chest Pain","Activity, Motor","Healthy Aging","Weight, Body","Inflammation","Gonadal Steroid Hormones","Neuronal Plasticity","Neuromuscular Manifestations","2026-05-28",{"date":100,"type":36},{"date":170,"type":36},"2026-05-17",{"date":172,"type":22},"2029-09",{"name":174,"class":77},"University of Houston",{"id":176,"slug":177,"hasResults":12,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":182,"targetDuration":4,"studyType":23,"phases":184,"briefSummary":185,"conditions":186,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":44},"100640575","treatment-of-acute-low-back-pain-with-transcutaneous-electrical-neurostimulation-in-emergency-departments-100640575","NCT07588490","Treatment of Acute Low Back Pain With Transcutaneous Electrical Neurostimulation in Emergency Departments","Treatment of Acute Low Back Pain With Transcutaneous Electrical Neurostimulation in Emergency Departments: a Randomised Controlled Trial","Inclusion Criteria:\n\n* = or \\> 18 years old\n* pain (EN \\> 3) related to acute lower back pain in the emergency department.\n\nExclusion Criteria:\n\n* Refusal to participate in the study, refusal to sign the informed consent form\n* Consent cannot be obtained (cognitive impairment, language barrier, etc.)\n* Patients with lower back pain lasting more than 6 weeks\n* Taking immediate-release pain medication within the last 6 hours\n* Taking extended-release pain medication within the last 12 hours\n* Taking a muscle relaxant within the last 24 hours\n* Pregnant women\n* Patients requiring immediate medical attention (life-threatening situation)\n* Patient already treated with TENS\n* Patient with a body temperature \\> 38°C\n* Patient with a known spinal infection\n* Lower back pain related to trauma\n* Patient with a known systemic rheumatological or spinal disease\n* Patient with a known systemic inflammatory disease\n* Patient with a known chronic pain condition such as fibromyalgia\n* Patient with pain radiating into the lower limb along the path of one of the following nerves (L3-L4-L5-S1)",{"count":183,"type":22},222,[89],"Acute low back pain is a common reason for emergency department visits (4.39% \\[95% CI: 3.67-5.18\\]). Drug treatment options are limited and largely ineffective. Paracetamol and opioids are no better than placebo for acute low back pain. Only NSAIDs and muscle relaxants have a slightly beneficial effect on pain, but muscle relaxants have an unfavorable benefit-risk ratio.\n\nGiven this situation, it is necessary to explore new non-pharmacological treatment options to relieve the pain of these patients. Transcutaneous electrical nerve stimulation (TENS) is a non-pharmacological therapy that involves applying an electrical current through the skin. Using one or two pairs of electrodes attached to the skin, TENS delivers painless, low-intensity electrical pulses to a painful area or along the path of a nerve.\n\nTENS works by selectively activating large-diameter, non-nociceptive afferent fibers to induce segmental analgesia. In addition, TENS increases the concentration of endorphins in the bloodstream and cerebrospinal fluid.\n\nThe use of TENS has been studied primarily in chronic low back pain. A 2007 Cochrane systematic review concluded that TENS appears to reduce pain and improve range of motion in subjects with chronic low back pain.\n\nThe use of TENS in the emergency department has been little studied. To our knowledge, there are no high-quality studies comparing TENS versus placebo for acute low back pain in patients presenting to an emergency department. This study aims to investigate the analgesic efficacy of TENS compared to placebo in the treatment of acute low back pain in the emergency department.",[30],"2026-05-08",{"date":189,"type":36},"2026-05-14",{"date":191,"type":36},"2026-01-12",{"date":193,"type":22},"2026-12-31",{"name":195,"class":77},"Cliniques universitaires Saint-Luc- Université Catholique de Louvain",{"id":197,"slug":198,"hasResults":12,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":202,"eligibilityCriteria":203,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":204,"enrollmentInfo":205,"targetDuration":4,"studyType":23,"phases":207,"briefSummary":209,"conditions":210,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":222},"100518173","phase-3-cares-comprehensive-analgesic-recovery-and-education-support-for-surgery-trial-100518173","NCT06027099","CARES (Comprehensive Analgesic, Recovery, and Education Support) for Surgery Trial","Integrating Tailored Postoperative Opioid Tapering and Pain Management Support for Patients on Long-Term Opioid Use Presenting for Surgery","CARES","INCLUSION CRITERIA:\n\n* 18 to 75 years of age\n* Able to speak, write, and read fluently in English\n* Scheduled for elective surgery at\n\n  * Stanford University Medical Center,\n  * Brigham and Women's Hospital (Harvard University),\n  * Atrium Health Wake Forest Baptist Medical Center (Wake Forest University), or\n  * University of Kansas Medical Center\n* Preoperative long-term opioid use (Defined as ≥ 60-day supply of opioids in the 180-day period prior to surgery), identified via self-report, state Prescription Drug Monitoring Program (PDMP), or Electronic Medical Records (EHR). Days may be nonconsecutive, and actual use of opioid supply is not required.\n* Willing and able to complete online assessments and study calls independently\n* On the preoperative Baseline assessments, least one of the following:\n\n  * Current Opioid Misuse Measure (COMM-17): score ≥ 9\n  * Tobacco, Alcohol, Prescription medication, and other Substance use (TAPS-1): Reported use more frequent than \"Never\" on any item except Tobacco; for Tobacco, \"Yes\" to at least one item on the TAPS-2 for Tobacco\n  * Alcohol Use Disorders Identification Test (AUDIT-C): score ≥4 (men), ≥3 (women)\n  * Modified Brief Pain Inventory (mBPI): \"Yes\" to at least one of the following:\n\n    * Over the past 24 hours have you needed to take your pain medication to help you sleep?\n    * Have you taken any pain medications for any reason other than your pain, such as to reduce anxiety or improve mood?\n    * Have you taken more pain medication than was prescribed to you in the past 24 hours?\n* At the Post-Operative Call (7-13 days post-op): Postoperative daily opioid dose ≥ preoperative daily opioid dose (identified during the Pre-Surgery Call 5-1 day before surgery), measured in Morphine Milligram Equivalents (MME).\n\nEXCLUSION CRITERIA\n\n* Infection, tumor, or fracture at the operative site\n* Allergy or intolerance to tizanidine\n* Current use of tizanidine\n* Renal impairment (Creatinine Clearance \\[CrCl\\] \\\u003C 25 ml\u002Fmin)\n* Hepatic impairment, including cirrhosis or elevated liver enzymes\n* Concurrent use of other α2-adrenergic agonists, skeletal muscle relaxants\n* Concurrent use of: fluvoxamine, ciprofloxacin,zileuton, fluoroquinolones, antiarrhythmics (amiodarone, mexiletine, propafenone, verapamil), cimetidine, famotidine, oral contraceptive pills, acyclovir, ticlopidine, and fexinidazole\n* Pre-existing hypotension, sedation, dizziness, severe respiratory insufficiency.\n* Opioid Use Disorder\n* Suicidality as assessed by the Patient Health Questionnaire-9 (PHQ-9) Question 9 score ≥ 1\n* Pregnancy, breastfeeding, or planning to conceive\n* Planned cancer treatment in the \\\u003C 3 months following surgery\n* Conditions causing inability to complete assessments (education, cognitive ability, mental status, medical status)\n* Participating in another clinical trial with an active treatment arm","75 Years",{"count":206,"type":22},375,[208],"PHASE3","The goal of this clinical trial is to learn whether a combined behavioral and pharmacologic intervention can help reduce opioid use, improve pain recovery, and prevent opioid misuse after surgery in adults undergoing elective surgery. The study includes adults aged 18 to 75 who have a history of long-term opioid use, defined as having access to opioids for 60 or more days within the 180 days before surgery.\n\nThe main questions it aims to answer are:\n\n* Does Motivational Interviewing with guided opioid tapering plus tizanidine (MI-Opioid Taper + Tizanidine) help participants return to their preoperative opioid use level or stop opioids faster than Enhanced Usual Care (EUC)?\n* Does the intervention reduce the time to pain resolution and decrease the likelihood of opioid misuse after surgery compared to EUC?\n\nResearchers will compare MI-Opioid Taper + Tizanidine to MI-Opioid Taper with placebo and to EUC to see whether the intervention improves postoperative opioid and pain outcomes.\n\nParticipants will:\n\n* Complete a phone assessment and baseline survey before surgery\n* Be randomly assigned 7-13 days after surgery to one of three groups:\n\n  * MI-Opioid Taper + tizanidine (MTT)\n  * MI-Opioid Taper + placebo (MTP)\n  * Enhanced Usual Care (EUC)\n* Complete brief weekly phone or video visits with a study clinician for 6 weeks starting 14 days after surgery\n* Take a study medication (tizanidine or placebo) three times daily for 5 weeks (MTT and MTP groups only)\n* Complete weekly online surveys for 6 months, followed by monthly surveys until 12 months after surgery to track pain, opioid use, and related outcomes",[211,30,158,212],"Chronic Pain","Opioid Misuse","2026-05-01",{"date":215,"type":36},"2026-05-06",{"date":217,"type":36},"2024-12-05",{"date":219,"type":22},"2028-07",{"name":221,"class":77},"Stanford University",4,{"id":224,"slug":225,"hasResults":12,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":4,"eligibilityCriteria":229,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":230,"targetDuration":232,"studyType":233,"phases":4,"briefSummary":234,"conditions":235,"keywords":237,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":44},"100547010","exploring-multimorbidity-in-patients-with-spinal-pain-100547010","NCT06402409","Exploring Multimorbidity in Patients With Spinal Pain","Workpackage 1: Baseline Prevalence and Implications of Multimorbidity for the Management of Spinal Pain Workpackage 2: The Influence of Multimorbidity Treatment Burden on Long-term Prognosis of Individuals With Spinal Pain","Inclusion Criteria:\n\n* 18 years old or above\n* Are diagnosed with neck or back pain\n* Diagnosis is established by or confirmed by a rheumatologist (clinical expert opinion)\n* Speak, read and understand Danish\n\nExclusion Criteria:\n\n* Withdraw consent",{"count":231,"type":22},2000,"1 Year","OBSERVATIONAL","Spinal pain is frequently accompanied by other chronic conditions (multimorbidity) and the predicted rise in multimorbidity prevalence emphasizes the need for studies to understand its impact on patients with chronic pain conditions.\n\nTherefore the aims of the two studies are to:\n\nWork package 1 - Determine prevalence of multimorbidity among patients with spinal pain referred to hospital outpatient clinics. Examine associations with relevant health-related factors and cover the significance of multimorbidity in the diagnostic process, referral patterns and healthcare utilization.\n\nWork package 2: Examine the association between treatment burden arising from multimorbidity and patient prognosis in structured rehabilitation.\n\nAcross both work packages data will be derived from individuals initially referred to the Department of Rheumatology at Aalborg University Hospital (AaUH) or the Medical Spine Clinic in Silkeborg (MSCS).",[30,158,236],"Comorbidities and Coexisting Conditions",[238,239,240,158,30,241],"Multimorbidity","Comorbidities","Comorbidity","Spinal pain","2026-04-09",{"date":244,"type":36},"2026-04-14",{"date":246,"type":36},"2024-04-01",{"date":248,"type":22},"2026-10-01",{"name":250,"class":77},"Jacob Christiansen Gandløse",{"id":252,"slug":253,"hasResults":12,"nctId":254,"briefTitle":255,"officialTitle":256,"acronym":4,"eligibilityCriteria":257,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":258,"enrollmentInfo":259,"targetDuration":4,"studyType":23,"phases":261,"briefSummary":262,"conditions":263,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":222},"100633603","health-effects-of-mindfulness-based-stress-reduction-course-in-treatment-of-back-pain-100633603","NCT07528833","Health Effects of Mindfulness Based Stress Reduction Course in Treatment of Back Pain","Health Effects of Mindfulness Based Stress Reduction Course Versus Usual Care in Treatment of Back Pain: a Randomized Clinical Trial","Inclusion Criteria:\n\n* Working-age (18-64 years) patients\n* Back pain in thoracal or lumbar area\n* NRS at least 4\n* With or without radiculative symptoms\n* Pain duration over 12 weeks\n* Pain can be localized or widespread\n* Also patients with multiple pain are eligible\n* X-ray or MRI scan is not needed\n* Patients can be both gender\n* Finnish language skills and adequate competence are needed for filling the survey forms and participation in interventions\n\nExclusion Criteria:\n\n* Pregnancy\n* Recent delivery (\\\u003C12 months)\n* Mental health problems with psychotic symptoms\n* Acute severe psychological trauma (3 months)\n* Sings of back infection\n* Acute severe trauma in the back (fracture)\n* surgery (\\\u003C 6 months)\n* planned surgery in the future\n* tumor in the back","64 Years",{"count":260,"type":22},120,[89],"* Health effects of mindfulness based stress reduction course versus usual care in treatment of back pain: a randomized clinical trial\n* Mindfulness based stress reduction (MBSR) course intervention for half of the research patients\n* MBSR course lasts for 8 weeks.\n* follow-up time 2 years.\n* research data is collected by Recdap\n* Working-age (18-64 years) patients with back pain in thoracal or lumbar area (NRS at least 4) with or without radiculation over 12 weeks will be recruited.\n* The primary outcome measure is Numeric pain rating scale (NRS, 0-10).",[30],"2026-04-07",{"date":244,"type":36},{"date":267,"type":36},"2025-01-01",{"date":269,"type":22},"2030-01-01",{"name":271,"class":77},"Tampere University Hospital",{"id":273,"slug":274,"hasResults":12,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":278,"eligibilityCriteria":279,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":280,"targetDuration":4,"studyType":23,"phases":282,"briefSummary":283,"conditions":284,"keywords":286,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":295,"completionDateStruct":297,"leadSponsor":299,"locationsCount":44},"100603530","psychological-options-for-wellness-and-recovery-power-trial-for-veterans-with-chronic-backneck-pain-100603530","NCT07137715","Psychological Options for Wellness and Recovery (POWeR) Trial for Veterans With Chronic Back\u002FNeck Pain","Pain Reprocessing Therapy for Veterans With Chronic Back Pain: Comparative Efficacy and Facilitators and Barriers to Implementation","POWeR","Inclusion Criteria:\n\n* Adults (18 and older)\n* Be veterans\n* Have a history of chronic back or neck pain defined as pain at least half the days of the last 6 months.\n* Have moderate or greater pain, defined as pain intensity ≥4 in the past week\n\nExclusion Criteria:\n\nClinical presentation suggestive of back pain that is secondary or peripheral in nature, including self-reported leg pain that is worse than back pain (indicative of radiculopathy or sciatica), spine surgery within the past 6 months, fall, motor vehicle accident or other trauma related to back pain in the past 6 months, back pain due to an inflammatory disorder, infection, or malignant etiology as determined per medical provider review, known sensory abnormality in trunk or legs, recent large (\\>20 lbs) unexplained weight loss, difficulty controlling bowels (to screen out cauda equina syndrome), and self-reported diagnoses of specific inflammatory disorders (rheumatoid arthritis, polymyalgia rheumatica, scleroderma, Lupus, and polymyositis).\n\nAdditionally, patients who meet any of the following criteria are ineligible due to anticipated difficulties complying with study procedures:\n\n* Moderate or severe cognitive impairment\n* Unstable or severe untreated mental health condition, including active suicidal ideation\n* Unstable or end-stage medical disease including active cancer\n* Back surgery planned within the next 6 months\n* Inability to communicate by telephone or video, including inability due to housing instability\n* Current pain-related litigation outside the VA (service connection-related applications are not excluded)\n* Having engaged in CBT or PRT for chronic pain in the past 6 months\n* Participants may be excluded based on the discretion of PIs Ashar and Frank",{"count":281,"type":22},360,[89],"The goal of this clinical trial is to learn which treatment works better for veterans with chronic neck or back pain. This study is comparing three treatments: Pain Reprocessing Therapy (PRT), Cognitive Behavioral Therapy (CBT), and usual care (whatever a person is already doing to cope with their pain).\n\nThe main questions the study aims to answer are:\n\n1. Which treatment works better for lowering pain: PRT, CBT, or usual care?\n2. How do the effects of PRT compare with CBT and usual care in terms of pain relief and other factors such as emotional functioning, quality of life, anxiety, and pain medication use?\n\nParticipants will:\n\n1. Be randomly assigned to receive either PRT, CBT, or usual care.\n2. Complete questionnaires about their pain and health.\n3. If in the PRT or CBT group, have nine weekly therapy sessions over video calls with a therapist.",[211,30,285,158],"Back Pain Lower Back Chronic",[287,288,211,289,158,30,290,291],"Pain Reprocessing Therapy (PRT)","PRT","Veterans","Cognitive Behavioral Therapy (CBT)","CBT","2026-03-30",{"date":294,"type":36},"2026-03-31",{"date":296,"type":36},"2026-03-27",{"date":298,"type":22},"2028-09",{"name":300,"class":77},"University of Colorado, Denver",{"id":302,"slug":303,"hasResults":12,"nctId":304,"briefTitle":305,"officialTitle":306,"acronym":4,"eligibilityCriteria":307,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":308,"targetDuration":4,"studyType":23,"phases":310,"briefSummary":311,"conditions":312,"keywords":317,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":335,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":340,"locationsCount":342},"100631700","active-coping-interdisciplinary-program-for-chronic-pain-physiotherapy-unit-spain-100631700","NCT07504094","Active Coping: Interdisciplinary Program for Chronic Pain, Physiotherapy Unit (Spain)","Interdisciplinary Active Coping Program for Chronic Pain in the Physiotherapy Unit in Primary Care - Teruel Health Sector (Aragón, Spain)","Inclusion Criteria:\n\n* Adult (18 years or older)\n* Diagnosis of non-oncological chronic back pain\n* Referred from Primary Care to the Physiotherapy Unit of Teruel Ensanche . (UFAP) from one of the following basic health zones: Teruel Centro, Teruel Ensanche, Albarracín, Alfambra, Cella, or Villel\n* Able to provide voluntary written informed consent\n\nExclusion Criteria:\n\n* Oncological pain\n* Cognitive impairment that prevents following the program\n* Spinal surgery in the last year\n* Internal electrostimulator device (e.g. pacemaker, spinal cord stimulator)",{"count":309,"type":22},20,[89],"The goal of this observational intervention study is to evaluate the impact of a multidisciplinary active coping program for chronic back pain in adults referred from Primary Care to the Physiotherapy Unit of Teruel Ensanche. The main questions it aims to answer are:\n\n* Does the program improve physical function, measured through gait speed, balance, and chair stand tests?\n* Does it reduce pain-related psychological factors such as kinesiophobia, catastrophizing, anxiety, and depression?\n* Does it improve quality of life and sleep quality, and reduce analgesic medication use?\n\nParticipants will attend group sessions on pain neuroscience education, followed by sessions on healthy habits, nutrition and sleep hygiene and group psychological intervention focused on emotional wellbeing tools, and will complete therapeutic exercise sessions over the course of the program. They will also complete validated questionnaires and physical assessments at three timepoints: at baseline, at the end of the program, and at a 6-month follow-up.",[313,211,30,314,315,316],"Chronic Back Pain","Low Back Pain, Chronic","Musculoskeletal Pain","Kinesiophobia",[318,319,320,321,322,313,323,324,325,326,327,328,329,330,331,332,333],"Pain Neuroscience Education","Therapeutic Exercise","Multidisciplinary Intervention","Active Coping","Psychological Intervention","Chronic Musculoskeletal Pain","Central Sensitization","Pain Catastrophizing","Primary Care","Physiotherapy","Primary Care Physiotherapy Unit","Quality of Life","Physical Function","Sleep Quality","Anxiety","Depression","2026-03-26",{"date":294,"type":36},{"date":337,"type":22},"2026-04-01",{"date":339,"type":22},"2028-02",{"name":341,"class":77},"Universidad de Zaragoza",2,{"id":344,"slug":345,"hasResults":12,"nctId":346,"briefTitle":347,"officialTitle":348,"acronym":4,"eligibilityCriteria":349,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":52,"enrollmentInfo":350,"targetDuration":4,"studyType":23,"phases":352,"briefSummary":353,"conditions":354,"keywords":355,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":361,"startDateStruct":362,"completionDateStruct":363,"leadSponsor":365,"locationsCount":342},"100631176","conventional-vs-pulsed-rf-in-coccydynia-100631176","NCT07497269","Conventional vs Pulsed RF in Coccydynia","Pulsed vs Conventional Radiofrequency of the Ganglion Impar for Coccydynia: A Prospective Randomized Trial","Inclusion Criteria:\n\n* Age between 18 and 80 years.\n* Chronic pain in the coccygeal region lasting longer than 3 months, unresponsive to analgesics, anti-inflammatory drugs, and other conservative treatment methods.\n* Patients scheduled to undergo ganglion impar treatment with either conventional or pulsed radiofrequency ablation (RFA).\n\nExclusion Criteria:\n\n* Incomplete medical records.\n* Loss to follow-up.\n* Technical failure during the block procedure.\n* Local infection, bleeding disorders, allergy to contrast agents, or history of spinal surgery.\n* History of malignancy.\n* Refusal to participate in the study.\n* Diagnosed psychological disorders.\n* Individuals unable to communicate effectively or understand instructions.\n* Age under 18 or over 80 years.",{"count":351,"type":22},90,[89],"The aim of this study is to prospectively evaluate the effects of pulsed and conventional radiofrequency ablation of the ganglion impar on pain, quality of life, and sleep quality in patients with refractory coccydynia, and to determine whether one treatment is superior to the other.",[30],[356,357,358,359],"Radiofrequency Ablation","low back pain","quality of life","coccyx","2026-03-24",{"date":296,"type":36},{"date":337,"type":22},{"date":364,"type":22},"2028-04-01",{"name":366,"class":77},"Adana City Training and Research Hospital",{"id":368,"slug":369,"hasResults":12,"nctId":370,"briefTitle":371,"officialTitle":372,"acronym":373,"eligibilityCriteria":374,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":375,"targetDuration":4,"studyType":23,"phases":376,"briefSummary":377,"conditions":378,"keywords":380,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":381,"lastUpdatePostDateStruct":382,"startDateStruct":384,"completionDateStruct":386,"leadSponsor":388,"locationsCount":390},"100414686","post-marketing-study-of-magnetos-easypack-putty-standalone-compared-to-demineralized-bone-matrix-or-fibers-mixed-with-autograft-in-patients-undergoing-posterolateral-lumbar-fusion-100414686","NCT04679844","Post Marketing Study of MagnetOs Easypack Putty Standalone Compared to Demineralized Bone Matrix or Fibers Mixed With Autograft in Patients Undergoing Posterolateral Lumbar Fusion","A Prospective, Randomized, Multi-Center Study to Assess the Safety and Performance of MagnetOs Easypack Putty Standalone Compared to Demineralized Bone Matrix or Fibers (DBX or Grafton) Mixed With Local Autograft in Patients Undergoing One to Two-Level Instrumented Posterolateral Lumbar\u002FThoracolumbar Fusion (PLF)","PROOF","Inclusion Criteria:\n\n* Patient is able to read\u002Fbe read, understand, and provide written informed consent and has signed the Institutional Review Board (IRB) approved informed consent.\n* Male or female patient ≥ 18 years old.\n* Patients with segmental mechanical spinal instability requiring arthrodesis surgery.\n\nInstability can be either caused by degenerative disc disease or by traumatic injury to the spinal column. Patient requiring a maximum of two-level instrumented posterolateral lumbar\u002Fthoraco-lumbar fusion (T11 - S1) will be enrolled. Mechanical instability is defined by the presence of one or more of the following:\n\n1. instability (angulation ≥ 5 degrees or translation ≥ 3 mm on flexion\u002Fextension radiographs),\n2. decreased disc height by \\> 2 mm, but dependent upon the spinal level\n3. Grade II or more listhesis\n4. TLICS equal or greater than 5\n5. Unstable burst fracture\n\n   * Failed conservative treatment (physical therapy, bed rest, medications, spinal injections, manipulations, or transcutaneous electrical nerve stimulation) for a minimum period of 3 months prior to study enrollment (if the patient undergoes elective surgery). Patients who have spinal instability (as defined above in inclusion criteria number three), caused by acute trauma requiring urgent surgical treatment are excluded from this criterion.\n\nExclusion Criteria:\n\n* Requires \\> two-level fusion or expected to need secondary intervention within one year following surgery.\n* Had prior PLF fusion or attempted PLF fusion at the involved levels.\n* Had previous decompression at the involved levels.\n* Women who are or intend to become pregnant within the next 12 months.\n* To treat conditions in which general bone grafting is not advisable.\n* In conditions where the surgical site may be subjected to excessive impact or stresses, including those beyond the load strength of fixation hardware (e.g. defect site stabilization is not possible).\n* In case of significant vascular impairment proximal to the graft site.\n* In case of severe metabolic or systemic bone disorders (e.g., osteogenesis imperfecta, history of or active Pott's disease, stage \\>4 renal disease or Paget's Disease) that affect bone or wound healing.\n* In case of acute and chronic infections in the operated area (soft tissue infections; inflammation, bacterial bone diseases; osteomyelitis).\n* When intraoperative soft tissue coverage is not planned or possible.\n* Receiving treatment with medication interfering with calcium metabolism.\n* Has degenerative disc disease (DDD) related to a benign or malignant tumor.\n* Has history or presence of active malignancy.\n* Has known substance abuse, psychiatric disorder, or a condition which, in the opinion of the investigator, may influence the healing or ability to comply with protocol requirements.\n* Is involved in active litigation relating to his\u002Fher spinal condition.\n* Has participated in an investigational study within 30 days prior to surgery for study devices.",{"count":21,"type":22},[89],"This is a phase IV post-marketing study for MagnetOs Easypack Putty. MagnetOs Easypack Putty is a synthetic bone graft extender product that is routinely used by surgeons as a treatment for patients with degenerative disc disease or spinal trauma undergoing spinal fusion surgery.\n\nIn this study, MagnetOs Easypack Putty will be used according to the latest U.S. Instructions For Use, standalone in the posterolateral spine.",[124,379,30],"Spine Fusion",[124,379],"2026-03-18",{"date":383,"type":36},"2026-03-20",{"date":385,"type":36},"2024-12-06",{"date":387,"type":22},"2027-08-30",{"name":389,"class":43},"Kuros Biosurgery AG",6,{"id":392,"slug":393,"hasResults":12,"nctId":394,"briefTitle":395,"officialTitle":396,"acronym":397,"eligibilityCriteria":398,"healthyVolunteers":113,"sex":18,"minAge":19,"maxAge":85,"enrollmentInfo":399,"targetDuration":4,"studyType":23,"phases":401,"briefSummary":402,"conditions":403,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":405,"lastUpdatePostDateStruct":406,"startDateStruct":408,"completionDateStruct":410,"leadSponsor":412,"locationsCount":44},"100601585","pain-intervention-with-needling-pilot-of-integrated-neuromodulation-techniques-100601585","NCT07112404","Pain Intervention With Needling: Pilot Of Integrated Neuromodulation Techniques","PINPOINT Study: Pain Intervention With Needling: Pilot Of Integrated Neuromodulation Techniques","PINPOINT","Inclusion Criteria:\n\n* Both males and females between the ages of 18 and 65 will be included in this study.\n\nPhase 1 Inclusion criteria\n\n\\- Healthy adults who report no pain for more than 1 day in the past 3 months in their lumbar region. Lumbar region will include posterior lumber musculature, lumbar spine, sacroiliac pain, or superior gluteal area pain.\n\nPhase 2 Inclusion criteria\n\n* Adults experiencing chronic low back pain. Chronic low back pain will be identified as having pain the lumbar region for at least 3 months. The pain may be constant or episodic in nature.\n* Participants will be included if they experience pain at least 75% of the days in the past 3 months. All pain levels will be included. Lumbar region will include posterior lumber musculature, lumbar spine, sacroiliac pain, or superior gluteal area pain.\n\nExclusion Criteria:\n\n* Individuals who are currently seeking any form of medical treatment for lumbar conditions beyond routine physician follow-up appointments in order to avoid confounding variables, regardless of pain-free status. These may include, but are not limited to, seeking treatment from a chiropractor, acupuncturist, or massage therapist or medical procedures such as injections into the lumbar region for pain.\n* Additionally, those with previous lumbar surgeries or those with previous major injuries to the lumbar spine that may have resulted in structural abnormalities that may compromise needle placement will be excluded. If surgical procedures did not alter structural alignment, then it will be allowed. For example, an approved procedure may include discectomy or nerve ablation, while a not approved procedure would include a lumbar fusion or scoliosis rod placement.\n* Additionally, if a person is experiencing radicular symptoms from a back injury, despite not feeling the symptoms in the lumbar region, will not be considered. Radicular symptoms will be defined as those present past the knee and\u002For electrical in nature. Individuals with neurological conditions or those who need the services of another due to cognitive deficits will not be considered for this study.\n* Furthermore, as this study relies on an intact sensory system, participants with conditions that may affect sensory processing (e.g., peripheral neuropathy, skin conditions, or circulatory disorders) will be excluded through careful screening.\n\nAdditional exclusion criteria\n\n* Will include the following conditions identified as contraindications for dry needling: those with impaired sensitivity, taking anticoagulants, a compromised immune system, a local or systemic infection, an active tumor, history of lymph node removal, history of autoimmune disease, allergy to metals such as nickel or chromium, history of cosmetic procedures in the area, pregnant individuals, or osteoporosis.\n* Non-English-speaking subjects will be excluded from the study due to the need to understand any communication while dry-needling procedures are taking place.",{"count":400,"type":22},42,[89],"The study's purpose is to determine the effects of three different dry needling sessions on pain and quality of life for those with chronic low back pain. Dry needling is a therapeutic procedure in which a very thin, monofilament needle is inserted through the skin to reach a target tissue like a muscle to help reduce pain, improve muscle activation, and increase blood flow. Dry needling has also been shown to improve nervous system function.",[404,30,123,329],"Pain","2026-03-11",{"date":407,"type":36},"2026-03-16",{"date":409,"type":36},"2025-10-23",{"date":411,"type":22},"2027-09",{"name":413,"class":77},"The University of Texas Medical Branch, Galveston",{"id":415,"slug":416,"hasResults":12,"nctId":417,"briefTitle":418,"officialTitle":419,"acronym":4,"eligibilityCriteria":420,"healthyVolunteers":113,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":421,"targetDuration":4,"studyType":23,"phases":422,"briefSummary":423,"conditions":424,"keywords":430,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":439,"startDateStruct":441,"completionDateStruct":442,"leadSponsor":444,"locationsCount":44},"100606549","neck-and-low-back-pain-in-physical-therapy-students-at-the-university-of-the-west-indies-mona-jamaica-100606549","NCT07177001","Neck and Low Back Pain in Physical Therapy Students at The University of the West Indies, Mona, Jamaica","The Prevalence of Neck and Low Back Pain With a Randomised Controlled Trial Comparing Spine-Specific and Non-Spine Specific Exercise Interventions in Physical Therapy Students at The University of the West Indies, Mona, Jamaica: A Two-Phase Study","Inclusion Criteria:\n\n1. All students enrolled in the Physical Therapy program at the University of the West Indies, Mona Campus, Jamaica during the period November 1, 2025 to October 31, 2026.\n2. Individuals who express a willingness to consent to the study.\n3. Individuals who express a willingness to adhere to the standardised exercise program for the stipulated period.\n\nExclusion Criteria:\n\n1. Individuals with a history of having spine surgery.\n2. Individuals who were previously diagnosed with spine pathology and currently receiving rehabilitation therapy.\n3. Individuals who express an unwillingness to participate in the study.",{"count":260,"type":22},[89],"The purpose of this study is to determine the prevalence of neck and low back pain among physical therapy students enrolled at The University of the West Indies, Mona. It also aims to assess students' knowledge, attitudes, and practices regarding spine health and to evaluate the effectiveness of an eight-week standardised spine-specific exercise programme in reducing musculoskeletal pain and improving functional status among those reporting symptoms. The study will be conducted in two phases, beginning with a descriptive cross-sectional assessment of prevalence, followed by a prospective randomised controlled trial in which students experiencing neck and\u002For low back pain will be allocated to either a spine-specific exercise intervention group or a non-spine-specific exercise control group for comparative analysis of outcomes.",[30,425,315,426,427,428,327,429,158],"Low Back Pain","Spine Health","Physical Therapy","Physiotherapist Students","Rehabilitation",[431,357,432,433,434,435,436,437],"lower back pain","neck pain","musculoskeletal pain","spine health","physical therapy students","physiotherapy students","rehabilitation","2026-02-20",{"date":440,"type":36},"2026-02-24",{"date":337,"type":22},{"date":443,"type":22},"2027-03-31",{"name":445,"class":77},"The University of The West Indies",{"id":447,"slug":448,"hasResults":12,"nctId":449,"briefTitle":450,"officialTitle":451,"acronym":4,"eligibilityCriteria":452,"healthyVolunteers":113,"sex":18,"minAge":19,"maxAge":85,"enrollmentInfo":453,"targetDuration":4,"studyType":23,"phases":455,"briefSummary":456,"conditions":457,"keywords":461,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":466,"startDateStruct":467,"completionDateStruct":468,"leadSponsor":469,"locationsCount":44},"100607914","the-prevalence-of-neck-and-low-back-pain-in-fmstrc-staff-at-the-uwi-mona-100607914","NCT07194746","The Prevalence of Neck and Low Back Pain in FMSTRC Staff At the UWI Mona","The Prevalence of Neck and Low Back Pain With a Randomised Controlled Trial Comparing Spine-Specific and Non-Spine Specific Exercise Interventions in Staff of the Faculty of Medical Sciences Teaching & Research Complex at The University of the West Indies, Mona, Jamaica: A Two-Phase Study","Inclusion Criteria\n\n1. All full time academic\u002Foffice\u002Fsupplementary\u002Fancillary staff employed to the Faculty of Medical Science, Training and Research Complex, UWI, Mona.\n2. Individuals with a willingness to adhere to exercise program given in a handout.\n3. Individuals age 18-65\n4. Individuals with at least 1 year experience in their current position.\n\nExclusion Criteria\n\n1. Individuals with a history of having spine surgery\n2. Individuals previously diagnosed with a spine pathology\n3. Individuals currently receiving physiotherapy for a spine problem",{"count":454,"type":22},200,[89],"The purpose of this study is to determine the prevalence of neck and low back pain among full-time staff at the Faculty of Medical Sciences Teaching and Research Complex (FMSTRC), The University of the West Indies, Mona. It also seeks to assess staff members' knowledge, attitudes, and practices regarding spine health and to evaluate the effectiveness of an eight-week standardised spine-specific exercise programme in reducing musculoskeletal discomfort among those experiencing neck and low back pain. The study will be conducted in two phases using a descriptive cross-sectional design followed by a prospective randomised controlled trial, in which participants reporting pain will be allocated to either a spine-specific exercise intervention group or a non-spine-specific exercise control group for comparative analysis of outcomes.",[158,30,315,425,458,459,460],"Spine","Work Related Illnesses","Work Related Musculoskeletal Disorders",[432,462,463,357,464,465],"back pain","Musculoskeletal pain","spinal health","work related musculoskeletal disorders",{"date":440,"type":36},{"date":337,"type":22},{"date":443,"type":22},{"name":445,"class":77},{"id":471,"slug":472,"hasResults":12,"nctId":473,"briefTitle":474,"officialTitle":475,"acronym":4,"eligibilityCriteria":476,"healthyVolunteers":113,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":477,"targetDuration":4,"studyType":23,"phases":479,"briefSummary":480,"conditions":481,"keywords":485,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":488,"startDateStruct":489,"completionDateStruct":490,"leadSponsor":491,"locationsCount":44},"100605850","low-back-and-neck-pain-in-nursing-students-at-the-university-of-the-west-indies-100605850","NCT07167888","Low Back and Neck Pain in Nursing Students at The University of The West Indies","The Prevalence of Neck and Low Back Pain With a Randomised Controlled Trial Comparing Spine-Specific and Non-Spine Specific Exercise Interventions in Nursing Students at The University of the West Indies, Mona: A Two-Phase Study","Inclusion Criteria:\n\n1. All students enrolled in the student nursing program at the University of the West Indies, Mona Campus, Jamaica during the period October 4, 2025 to October 3, 2026.\n2. Individuals who express a willingness to consent to the study.\n3. Individuals who express a willingness to adhere to the standardised exercise program for the stipulated period.\n\nExclusion Criteria:\n\n1. Individuals with a history of having spine surgery.\n2. Individuals who were previously diagnosed with spine pathology and currently receiving rehabilitation therapy.\n3. Individuals who express an unwillingness to participate in the study.",{"count":478,"type":22},400,[89],"The purpose of this study is to identify the prevalence of neck and low back pain in nursing students enrolled at the University of the West Indies, Mona; to assess their knowledge, attitude and practice of good spine health and to determine the outcome of a standardised spine exercise program on nursing students experiencing neck and low back pain, using a prospective randomised control design.",[30,425,315,158,426,482,123,483,484],"Musculoskeletal Pain Disorder","Nursing Students","Preclinical Education",[431,357,433,432,437,486,487,434],"university student","nursing students",{"date":440,"type":36},{"date":337,"type":22},{"date":443,"type":22},{"name":445,"class":77},{"id":493,"slug":494,"hasResults":12,"nctId":495,"briefTitle":496,"officialTitle":497,"acronym":498,"eligibilityCriteria":499,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":204,"enrollmentInfo":500,"targetDuration":4,"studyType":23,"phases":502,"briefSummary":503,"conditions":504,"keywords":506,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":511,"lastUpdatePostDateStruct":512,"startDateStruct":514,"completionDateStruct":516,"leadSponsor":518,"locationsCount":44},"100444352","phase-2-cannabidiol-for-reduction-of-brain-neuroinflammation-100444352","NCT05066308","Cannabidiol for Reduction of Brain Neuroinflammation","Evaluation of Cannabidiol for Reduction of Brain Neuroinflammation","CBD","Inclusion Criteria:\n\n1. Age ≥ 18 and ≤ 75;\n2. The ability to give written, informed consent;\n3. Fluency in English;\n4. Average worst daily pain of at least 4 on a 0-10 scale of pain intensity, during a typical day. Pain needs to be present for at least 50% of days during a typical week;\n5. On a stable pain treatment (pharmacological or otherwise) for the previous four weeks;\n6. Diagnosis of chronic low back pain, ongoing for at least 6 months prior to enrollment.\n7. High or mixed affinity binding to \\[11C\\]PBR28 identified by the Ala147Thr TSPO polymorphism in the TSPO gene (rs6971)\n\nExclusion Criteria:\n\n1. Outpatient surgery within 2 weeks and inpatient surgery within 1 month of the time of scanning (this timeframe may be extended if they are not fully recovered from the surgery);\n2. Elevated baseline transaminase (ALT and AST) levels above 3 times the Upper Limit of Normal (ULN), accompanied by elevations in bilirubin above 2 times the ULN;\n3. Any interventional pain procedures within 6 weeks prior to scanning procedure or at any point during study enrollment;\n4. Surgical intervention or introduction\u002Fchange in opioid regimen at any point during study enrollment;\n5. Contraindications to fMRI scanning and PET scanning (including presence of a cardiac pacemaker or pacemaker wires, metallic particles in the body, vascular clips in the head or previous neurosurgery, prosthetic heart valves, claustrophobia);\n6. Implanted spinal cord stimulator (SCS) for pain treatment;\n7. Any history of neurological illness or major medical illness, unless clearly resolved without long-term consequences;\n8. Current or past history of major psychiatric illness (PTSD, depression, and anxiety are exclusion criteria only if the conditions were so severe as to require hospitalization in the past year);\n9. Harmful alcohol drinking as indicated by an AUDIT score ≥ 16;\n10. Pregnancy or breast feeding;\n11. History of head trauma requiring hospitalization;\n12. Major cardiac event within the past 10 years;\n13. Regular use of recreational drugs in the past 3 months;\n14. Use of cannabis-containing products, such as products containing THC or over the-counter or dispensary CBD, for 2 weeks prior to starting the study medication and during the 4 weeks of taking the study medication;\n15. Use of immunosuppressive medications, such as prednisone, TNF medications within 2 weeks of the visit;\n16. Current bacterial or viral infection likely affecting the central nervous system;\n17. Epilepsy;\n18. Use of the medications valproate and clobazam, which may increase risk of hepatic AEs;\n19. Safety concerns related to use of any of the following medications will be discussed on an individualized basis with a physician:\n\n    * Strong and moderate CYP3A4 inhibitors including boceprevir, cobicistat, conivaptan, danoprevir, elvitegravir, ritonavir, indinavir, itraconazole, ketoconazole, lopinavir, paritaprevir and ombitasvir and\u002For dasabuvir, posaconazole, saquinavir and telaprevir, tipranavir, clarithromycin, diltiazem, idelalisib, nefazodone, nelfinavir, troleandomycin, voriconazole, aprepitant, cimetidine, ciprofloxacin, clotrimazole, crizotinib, cyclosporine, dronedarone, erythromycin, fluconazole, fluvoxamine, imatinib, tofisopam, disulfiram, and verapamil;\n    * Strong and moderate inhibitors of CYP2C19 including fluoxetine and ticlopidine;\n    * Sensitive and moderately sensitive substrates of CYP2C19 including clobazam, lansoprazole, omeprazole, S-mephenytoin, and rabeprazole;\n    * Sensitive and moderately sensitive substrates of CYP1A2 including alosetron, duloxetine, ramelteon, tasimelteon, theophylline, tizanidine, pirfenidone, and ramosetron;\n    * Sensitive and moderately sensitive substrates of CYP2B6 including bupropion and efavirenz;\n    * Sensitive and moderately sensitive substrates of CYP2C8 including repaglinide, montelukast, pioglitazone, and rosiglitazone;\n    * Sensitive and moderately sensitive substrates of CYP2C9 including tolbutamide, celecoxib, glimepiride, and warfarin;\n    * Sensitive and moderately sensitive substrates of UGT1A9 including diflunisal, propofol, and fenofibrate;\n    * Sensitive and moderately sensitive substrates of UGT2B7 including, gemfibrozil, lamotrigine, and morphine;\n20. CNS depressants including all antipsychotics, benzodiazepines (except for alprazolam, clonazepam, and lorazepam, which have low binding affinity to TSPO44-48), and non-benzodiazepine sleep aids that have a known unsafe reaction with CBD;\n21. Use of opioids ≥ 30 mg morphine equivalents on average per month;\n22. Actively suicidal, history of suicide attempt or an aborted attempt within the last 5 years, or engagement in non-suicidal self-injurious behavior within the last year;\n23. Allergy to sesame oil, and any other ingredients of EPIDIOLEX;\n24. Any other contraindications to CBD administration noted by the study physician;\n25. Any significant change in drug use and pain treatment from screening visit;\n26. In the opinion of the investigators, unable to safely participate in this study and\u002For provide reliable data (e.g., unable to reliably rate pain; unlikely to remain still during the imaging procedures, etc).",{"count":501,"type":22},80,[26],"This study will investigate whether cannabidiol (CBD), the primary centrally and peripherally active non-intoxicating compound in the cannabis plant, exerts anti-neuroinflammatory effects in patients with chronic low back pain (cLBP) with or without mild-to-moderate depression.",[30,505],"Depressive Symptoms",[462,507,508,509,510],"depression","depressive symptoms","cannabis","cannabidiol","2026-02-04",{"date":513,"type":36},"2026-02-06",{"date":515,"type":36},"2022-01-04",{"date":517,"type":22},"2026-12-15",{"name":519,"class":77},"Massachusetts General Hospital",{"id":521,"slug":522,"hasResults":12,"nctId":523,"briefTitle":524,"officialTitle":525,"acronym":4,"eligibilityCriteria":526,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":204,"enrollmentInfo":527,"targetDuration":4,"studyType":23,"phases":528,"briefSummary":529,"conditions":530,"keywords":533,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":548,"lastUpdatePostDateStruct":549,"startDateStruct":550,"completionDateStruct":552,"leadSponsor":554,"locationsCount":44},"100623073","musical-mindfulness-for-pain-in-the-ed-waiting-room-100623073","NCT07391891","Musical Mindfulness for Pain in the ED Waiting Room","Use of Music Mindfulness for Pain Management in the ED Waiting Room","Inclusion Criteria:\n\n* \\- Age \\>= 18 years old and \\\u003C=75 years old\n* Patient presents with neck or back pain",{"count":21,"type":22},[89],"Studies have shown that 60-70% of patients in the Emergency Department (ED) experience pain. With pain being such a broad issue in the ED, the ED is expected to deliver safe and effective treatment of pain. However, with the current ongoing opioid epidemic, it is important to consider other methods, both pharmacologic and nonpharmacologic, of pain reduction. Jazz music specifically has been demonstrated to have therapeutic effects on pain that can be used to lower the quantity of opioids administered to patients.\n\nNon-pharmacological interventions in the emergency department for pain typically consist of splinting an injury, applying heat or cold, or various distractions following initial and sequential pain assessment. Pharmacological interventions for pain in the Emergency Department involve the administration of acetaminophen, muscle relaxers, topical anesthetics, opioids, to name a few.\n\nIn the emergency department (ED), providers are increasingly hesitant to prescribe opioids over the past decade due to the current opioid epidemic, in which there is an increasing proportion of people that develop an addiction to opioids, including those that are prescribed to them for pain management.. While emergency medicine providers' decrease in opioid prescriptions pertains to their implementation of opioid-prescribing policies, little evidence has been found demonstrating a direct link in these policies to decreases in substance misuse. Consequently, providers find themselves needing to become ingenious in their approach to pain in patients through the integration of pharmacologic and non-pharmacologic mediums of analgesia.\n\nA recent randomized controlled trial (RCT) from Brigham and Women's Hospital in Boston sought to identify the qualitative responses from patients in the ED following the arbitrary distribution of either supervised or unsupervised music therapy over a time period of 4 hours. The initial results found that, generally speaking, music therapy may lower reported pain and anxiety scores. Furthermore, stronger results were identified in case subjects with higher initial reports of pain via a pain catastrophizing scale, implying that a higher baseline of pain results in more relief from music therapy. One shortcoming in the article is the lack of analysis with reported results and the biopsychosocial model of pain. Heavy emphasis is placed on the psychological and social components of pain in the Brigham and Women's article through the implementation of the Pain Catastrophizing Scale and Brief Pain Inventory scoring done during the RCT, but no focus on linked biological changes in the subjects through the music therapy intervention.\n\nThe purpose of this study is to (i.) assess the effect of a video training about musical pain management followed by a 15-minute music listening intervention on self-reported pain scores in ED patients with neck and back pain. The investigators also aim to (ii.) evaluate patient satisfaction and emotional response following the intervention. Opioid medications are commonly used to reduce substantial pain, and music therapy has been found to reduce associated pain and anxiety in patients, then the use of music therapy could be an aid in medicine to reduce opioid intake. The investigators hypothesize that the usage of a training on musical pain management combined with a specified jazz musical intervention will produce a significantly lower measured pain score in comparison to a video on mindful pain management followed by the patient's choice of activities.",[531,532,30],"Music Therapy for Pain and Sedation","Neck Pain Musculoskeletal",[534,535,536,537,538,539,540,541,542,543,462,432,544,433,545,546,547],"Music therapy","Music pain management","Musical pain managament","Opioid epidemic","Therapeutic medicine","Emergency Medicine","Emergency Room","Waiting Room","Music intervention","Jazz music","musculoskeletal","pain","pain management","music","2026-01-29",{"date":513,"type":36},{"date":551,"type":22},"2026-02-15",{"date":553,"type":22},"2026-04-30",{"name":555,"class":77},"University of California, Irvine",{"id":557,"slug":558,"hasResults":12,"nctId":559,"briefTitle":560,"officialTitle":560,"acronym":4,"eligibilityCriteria":561,"healthyVolunteers":12,"sex":18,"minAge":114,"maxAge":562,"enrollmentInfo":563,"targetDuration":4,"studyType":23,"phases":565,"briefSummary":566,"conditions":567,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":568,"lastUpdatePostDateStruct":569,"startDateStruct":571,"completionDateStruct":573,"leadSponsor":575,"locationsCount":44},"100443295","phase-3-safety-and-efficacy-of-oral-cannabis-in-chronic-spine-pain-100443295","NCT05052541","Safety and Efficacy of Oral Cannabis in Chronic Spine Pain","Some inclusion\u002Fexclusion criteria are purposely omitted at this time to preserve scientific integrity. They will be included after the trial is complete.\n\nInclusion Criteria:\n\nSelf-reported chronic (≥3 months' duration), non-radicular spine pain\n\nExclusion Criteria:\n\nUnwilling\u002Funable to refrain from cannabis use (medical or recreational) for 14 days prior to Baseline Visit and throughout the study (other than study drug). This includes whole plant inhalation, edibles, extracts, and topicals.\n\nCo-morbid cancer-related pain condition\n\nNeuropathic Pain\n\nA co-morbid pain condition that is of greater severity than the patient's spine pain\n\nSpine or other major surgery within the 3 months prior to enrollment\n\nPlanned surgery or procedural intervention during the study period\n\nAllergy or adverse reaction to cannabis\n\nCurrent or historical substance use disorder\n\nCurrent or historical alcohol use disorder\n\nCurrent or prior cannabis abuse\u002Fdependence\n\nPositive result for use of amphetamine\u002Fmethamphetamine, barbiturates, benzodiazepines, cocaine, phencyclidine (PCP), ecstasy (MDMA), as detected on urine screen\n\nCurrent use of valproate, clobazam, clopidogrel, warfarin, barbiturates, benzodiazepines\n\nPrior adverse reaction to cannabis exposure (paranoia, anxiety, etc.)\n\nHistory or diagnosis of schizophrenia, bipolar or a psychotic disorder\n\nHistory of any mental health illness that in the opinion of the Investigator would compromise the safety of the participant\n\nCurrent or historical severe depression\n\nCurrent suicidal ideation\n\nDiagnosed cognitive impairment (e.g. Alzheimer's Disease, traumatic brain injury)\n\nUncontrolled hypertension (\\>139\u002F89)\n\nAbnormal values on CBC (complete blood count) or CMP (comprehensive metabolic panel) laboratory analysis that are deemed clinically significant by study physician\n\nKnown hepatic disease or dysfunction, or identification of such on screening laboratory studies\n\nKnown cardiovascular disease\n\nAbnormal result on electrocardiogram (ECG) that is deemed clinically significant by study MD\n\nCognitive disability that interferes with ability to provide consent or understand study procedure\n\nHistory of seizure disorder\n\nAny medical condition for which immunosuppressive therapy is required.\n\nInability to refrain from using tobacco for at least 4 hours\n\nPresence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the participant or the quality of the data\n\nPending legal action or workers compensation\n\nPregnant females or females intending to become pregnant during the study period\n\nUnwilling to use one of the accepted forms of contraception during the study period and for at least 60 days after completion of the study (females of childbearing potential and males with sexual partners of childbearing potential)\n\nLactating females\n\nAnalgesia Arm Exclusion Criteria:\n\nUnwilling\u002Funable to discontinue current opioid use for 14 days prior to Baseline study visit and throughout the study\n\nReduction Arm Exclusion Criteria:\n\nNot interested in reducing or discontinuing use of prescribed opioids for chronic pain\n\nUnwilling to allow the study team to communicate with the participant's opioid prescribing provider\n\n\\*Some inclusion\u002Fexclusion criteria are purposely omitted at this time to preserve scientific integrity. They will be included after the trial is complete.","84 Years",{"count":564,"type":22},157,[208],"The overall objectives of this study are to investigate the efficacy of extended cannabis treatment to reduce patient exposure to prescription opioids through its use 1) as a non-opioid analgesic treatment, and 2) as a therapy for reducing high-dose opioid use in patients with chronic spine pain.",[30,158],"2026-01-21",{"date":570,"type":36},"2026-01-23",{"date":572,"type":22},"2026-01",{"date":574,"type":22},"2027-06",{"name":300,"class":77},{"id":577,"slug":578,"hasResults":12,"nctId":579,"briefTitle":580,"officialTitle":581,"acronym":4,"eligibilityCriteria":582,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":583,"targetDuration":4,"studyType":23,"phases":584,"briefSummary":585,"conditions":586,"keywords":589,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":592,"startDateStruct":594,"completionDateStruct":596,"leadSponsor":597,"locationsCount":44},"100509152","phase-1-dose-escalation-pilot-study-to-evaluate-the-safety-of-alocyte-for-the-treatment-of-facetogenic-back-pain-100509152","NCT05909709","Dose Escalation Pilot Study to Evaluate the Safety of Alocyte for the Treatment of Facetogenic Back Pain","An Open Label Dose Escalation Pilot Study to Evaluate the Safety of Alocyte Delivered Via Intra-articular Facet Injection for the Treatment of Facetogenic Back Pain","Inclusion Criteria:\n\n* In order to be eligible to participate in this study, all individuals must meet all of the following criteria:\n\n  1. Subjects age \\> 18 years at the time of signing the Informed Consent Form.\n  2. Male or Female.\n  3. Ability of participant to understand and the willingness to sign a written informed consent document.\n  4. Facetogenic back pain diagnosed using the following diagnostic criteria Subjects who have chronic low back pain based on clinical evaluation. Pain onset at dorsal extension and release at flexion is often considered suggestive for facet pain, even if non-specific, such as maximal tenderness upon deep palpation of posterior elements.\n  5. Patient with up to 5 diseased facet joints\n  6. Chronic Facetogenic pain (≥ 6 months) in patients that have failed conservative management\n  7. Subjects must be reasonably able to return for multiple follow-up visits.\n  8. For Women of Child-Bearing Potential (WOCBP) only, willingness to use FDA-recommended birth control until 6 months post treatment.\n  9. Any male subject must agree to use contraceptives and not donate sperm during the study.\n\nExclusion Criteria:\n\n1. Previous surgical intervention for back pain\n2. Previous stem cell injection(s) within the last year\n3. Use of anticoagulation or NSAIDs within 5 days of the injection\n4. MRI finding of severe high-grade lumbar stenosis\n5. Leg pain exceeding back pain\n6. Pain worse with flexion maneuvers\n7. Fracture of lumbar vertebrae\n8. Inability to perform any of the assessments required for endpoint analysis.\n9. Clinically significant abnormal screening laboratory or clinical assessment values\n10. Use of medications during the early phase of treatment such as chronic narcotic use, systemic corticosteroid administration, local corticosteroid injection at facets anticoagulant therapy and viscosupplementation into facets, any investigational drug used within 3 months prior to screening or during study and surgery in the facets\n11. Subjects with serious co-morbidities are excluded.\n12. Evidence of inflammatory arthritis (example, rheumatoid arthritis and ankylosing spondylitis) or traumatic fractures, osteoarthritis, meniscoid entrapment, synovial impingement, joint subluxation, synovial inflammation, loss of cartilage, and mechanical injury.\n13. Have a clinical history of malignancy within 5 years (i.e., subjects with prior malignancy must be disease free for 5 years), except curatively treated basal cell carcinoma, squamous cell carcinoma, melanoma in situ or cervical carcinoma, if recurrence occurs.\n14. Be currently participating (or participated within the previous 6 months) in an investigational therapeutic or device trial.\n15. Exhibiting signs of moderate or severe chronic respiratory disease (such as COPD, asthma, or pulmonary fibrosis).\n16. Patient with rheumatologic disorders.\n17. History of chronic liver disease or patient showing signs of clinical jaundice at the time of screening.\n18. History of severe chronic kidney disease or requiring dialysis.\n19. Patient with NYHA Class III or IV congestive heart failure or life-threatening arrhythmias.\n20. Subjects with a history of bleeding disorders, anticoagulation therapy that cannot be stopped as prior to the treatment.\n21. Any unstable condition of clinical significance, e.g., uncontrolled hypertension, unstable angina pectoris, worsening asthma.\n22. Hydroxychloroquine, oral or parenteral corticosteroids, immunosuppressants, or immunomodulating agents within 21 days prior to the Day 0\u002Ftreatment visit.\n23. Be a female who is pregnant, nursing, or of childbearing potential while not practicing effective contraceptive methods. Female subjects must undergo a blood pregnancy test at screening which will be within 72 hours of the IP infusion.\n24. Subject has a body mass index (BMI) greater than 42 kg\u002Fm2\n25. Subject has or had an active infection requiring systemic antibiotics within 12 weeks of enrollment in the study\n26. Inability to perform any of the assessments required for endpoint analysis.\n27. Active listing (or expected future listing) for transplant of any organ.\n28. Be a solid organ transplant recipient. This does not include prior cell-based therapy (\\>12 months prior to enrollment), bone, skin, ligament, tendon or corneal grafting. Have a history of organ or cell transplant rejection.\n29. History of drug abuse (illegal \"street\" drugs except marijuana, if it is legal to use in states where patient resides), or prescription medications not being used appropriately for a pre-existing medical condition or alcohol abuse (≥ 5 drinks\u002Fday for ˃ 3 months), or documented medical, occupational, or legal problems arising from the use of alcohol or drugs within the past 24 months\n30. Patients with untreated HIV infection. However, patients can be enrolled if have been treated for HIV and the test negative for HIV viral load but still test positive for antibodies.",{"count":87,"type":22},[25],"The purpose of this study is to see if the use of Alocyte (cord blood plasma plus mononucleic cells) will be safe, well tolerated, and whether it causes any side effects. The study will also examine if the use of the Investigational Product (IP) is able to reduce local inflammation or alleviate Facetogenic back pain",[587,30,588],"Facet Joints; Degeneration","Facet Joint Pain",[590,591],"Back pain","Facet joint pain",{"date":593,"type":36},"2026-01-13",{"date":595,"type":36},"2024-04-29",{"date":248,"type":22},{"name":598,"class":77},"Alimorad Farshchian",{"id":600,"slug":601,"hasResults":12,"nctId":602,"briefTitle":603,"officialTitle":604,"acronym":605,"eligibilityCriteria":606,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":607,"targetDuration":4,"studyType":23,"phases":609,"briefSummary":610,"conditions":611,"keywords":612,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":617,"lastUpdatePostDateStruct":618,"startDateStruct":620,"completionDateStruct":621,"leadSponsor":623,"locationsCount":44},"100528451","the-effect-of-chiropractic-care-on-opioid-use-for-chronic-spinal-pain-a-feasibility-study-100528451","NCT06160947","The Effect of Chiropractic Care on Opioid Use for Chronic Spinal Pain: A Feasibility Study","Impact of Chiropractic Care on Opioid Use Among Adults With Chronic Non-Cancer Spinal Pain: A Pilot Cluster Randomized Controlled Trial (ACCESS-DC Pilot)","ACCESS-DC","Inclusion Criteria:\n\nClusters\n\n* CHC in Canada\n* Roster of ≥ 3,500 patients\n* One or more opioid-reducing strategies implemented as part of their standard medical services (e.g., chart audits, tracked performance metrics related to high dose prescribing)\n\nParticipants\n\n* Adult patients (aged ≥ 18 years)\n* Diagnosis of chronic non-cancer spinal pain (i.e., back or neck pain of ≥ 12 weeks' duration, not associated with cancer)\n* Actively receiving one or more opioid prescriptions (minimum dose of 50 mg MED, dispensed over a period of at least 3 consecutive months)\n* Interested in reducing their opioid dose\n* Cognitive ability and language skills required to complete the outcome measures\n* Provision of informed consent\n\nExclusion Criteria:\n\nClusters\n\n• CHCs that employ chiropractors or have currently established chiropractic programs\n\nParticipants\n\n* Individuals already receiving chiropractic care\n* Opioid-naive (or \\\u003C 90 consecutive days of opioid prescription) at baseline\n* Total active opioid dosage of \\\u003C 50 mg MED at baseline\n* Actively receiving treatment for opioid use disorder (e.g., methadone, naloxone)\n* Spinal neoplasms or other 'red flag' diagnoses (e.g., fractures, infections, inflammatory arthritis, or cauda equina syndrome)\n* Anticipated problems with the participant being available for follow-up (e.g., incarceration, or planned incarceration)\n* The participant is or may be enrolled in a competing trial\n* Prior enrolment in the ACCESS-DC trial\n* Other reason to exclude the participant, as approved by the Methods Centre",{"count":608,"type":22},24,[89],"The investigators will conduct a pilot cluster randomized controlled trial (RCT) of chiropractic care added to usual medical care, versus usual medical care alone, for adult patients prescribed opioid therapy for chronic non-cancer spinal pain at four community health centers (CHCs) in Canada. These centers provide services to communities and vulnerable populations with high unemployment rates, multiple co-morbidities, and high rates of chronic musculoskeletal disorders that are commonly managed with prescription opioids.\n\nThe investigators hypothesize that a full-scale (definitive) cluster RCT on the impact of chiropractic care on prescription opioid use for chronic non-cancer spinal pain will be feasible within the Canadian CHC context.",[30],[613,614,615,616],"Clinical trials, randomized","Feasibility study","Analgesics, opioid","Chiropractic","2026-01-05",{"date":619,"type":36},"2026-01-07",{"date":337,"type":22},{"date":622,"type":22},"2028-03-31",{"name":624,"class":77},"McMaster University",{"id":626,"slug":627,"hasResults":12,"nctId":628,"briefTitle":629,"officialTitle":630,"acronym":631,"eligibilityCriteria":632,"healthyVolunteers":12,"sex":148,"minAge":633,"maxAge":19,"enrollmentInfo":634,"targetDuration":4,"studyType":23,"phases":635,"briefSummary":636,"conditions":637,"keywords":638,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":642,"lastUpdatePostDateStruct":643,"startDateStruct":645,"completionDateStruct":647,"leadSponsor":649,"locationsCount":342},"100617543","effect-of-shock-wave-therapy-with-core-stability-exercises-for-treatment-of-chronic-non-specific-back-pain-100617543","NCT07319988","Effect of Shock Wave Therapy With Core Stability Exercises for Treatment of Chronic Non-Specific Back Pain","A Randomized Controlled Trial Investigating the Effect of Extracorporeal Shock Wave Therapy With Core Stability Exercises for Treatment of Chronic Non-Specific Back Pain in Jordanian University Students","ESW","Inclusion Criteria:\n\n* chronic non- specific back pain for more than 3 months\n* teaching hours from 4 to 6 hours, 4 days per week\\\\\n* female sufferers\n* Body Mass Index 20 - 22\n\nExclusion Criteria:\n\n* No History of previous back surgeries\n* no history of discogenic lesion\n* overweight","16 Years",{"count":116,"type":22},[89],"To investigate the Effect of Combined Extracorporeal Shock Wave with core stability Exercise for the Treatment of Chronic Non-Specific Back Pain in Jordanian University Students",[30],[639,640,641],"Shock Wave","Core stability exercises","chronic non- specific back pain","2025-12-20",{"date":644,"type":36},"2026-01-06",{"date":646,"type":36},"2025-12-01",{"date":648,"type":22},"2026-06-01",{"name":650,"class":77},"New Ismailia National University",{"id":652,"slug":653,"hasResults":12,"nctId":654,"briefTitle":655,"officialTitle":656,"acronym":657,"eligibilityCriteria":658,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":85,"enrollmentInfo":659,"targetDuration":4,"studyType":23,"phases":660,"briefSummary":661,"conditions":662,"keywords":663,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":668,"lastUpdatePostDateStruct":669,"startDateStruct":671,"completionDateStruct":673,"leadSponsor":675,"locationsCount":4},"100611561","acute-effects-of-hot-pack-therapy-in-low-back-pain-100611561","NCT07242183","Acute Effects of Hot-Pack Therapy in Low Back Pain","Acute Effects of Hot-pack Therapy on Lumbar Erector Spinae Muscle Stiffness and Pain in Adults With Low Back Pain: A Randomised Controlled Trial.","HOTPACK-LBP","Inclusion Criteria:\n\n* Adults aged 18-65 years\n\nNonspecific\u002Fmechanical low back pain (clinical diagnosis)\n\nBaseline pain ≥3\u002F10 on a 0-10 Visual Analogue Scale (VAS)\n\nAble to understand procedures and provide written informed consent\n\nAble to attend baseline, immediate post-session, and 24-48 h follow-up assessments\n\nExclusion Criteria:\n\n* Neurologic deficit, tumour, or systemic inflammatory disease\n\nPrior lumbar spine surgery\n\nHeat or cold therapy to the lumbar region within the past 6 weeks\n\nDermatologic lesions, open wounds, or skin conditions over the lumbar area\n\nContraindications to heat (e.g., impaired sensation\u002Fneuropathy over the area, severe circulatory disorders)\n\nPregnancy\n\nImplanted electronic devices (e.g., pacemaker)\n\nInability to comply with the study schedule or procedures",{"count":608,"type":22},[89],"This single-centre, parallel-group randomized controlled trial will test whether one session of moist hot-pack therapy produces immediate improvements in pain intensity and lumbar erector spinae muscle stiffness in adults with nonspecific low back pain. Participants are randomized 1:1 to hot-pack or sham (room-temperature pack). Outcomes are assessed at baseline and immediately after the session using VAS (0-10 cm) and MyotonPro; a short follow-up (24-48 h) captures Oswestry Disability Index (ODI) and perceived change. The intervention is brief, low-risk, and commonly used in clinical practice, yet high-quality evidence on its acute effects is limited.",[425,30],[664,665,666,667],"Hot-pack","Muscle Stiffness","Erector Spinae","Myotonometry","2025-11-17",{"date":670,"type":36},"2025-11-21",{"date":672,"type":22},"2025-11-10",{"date":674,"type":22},"2025-12-30",{"name":676,"class":77},"Erzurum Technical University",{"id":678,"slug":679,"hasResults":12,"nctId":680,"briefTitle":681,"officialTitle":681,"acronym":4,"eligibilityCriteria":682,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":683,"targetDuration":4,"studyType":23,"phases":684,"briefSummary":685,"conditions":686,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":689,"lastUpdatePostDateStruct":690,"startDateStruct":692,"completionDateStruct":694,"leadSponsor":696,"locationsCount":44},"100450190","stress-and-opioid-misuse-risk-the-role-of-endogenous-opioid-and-endocannabinoid-mechanisms-100450190","NCT05142267","Stress and Opioid Misuse Risk: The Role of Endogenous Opioid and Endocannabinoid Mechanisms","Inclusion Criteria:\n\n* Intact cognitive status and ability to provide informed consent\n* Ability to read and write in English sufficiently to understand and complete study questionnaires (which are only validated in English)\n* Age 18 or older And\n* Presence of persistent daily low back pain of at least three months duration and of at least a 3\u002F10 in average intensity\n\nExclusion Criteria:\n\n* History of renal or hepatic dysfunction\n* Reports of current or past alcohol or substance abuse or treatment for such condition\n* A reported history of PTSD, psychotic, or bipolar disorders\n* Chronic pain due to malignancy (e.g., cancer) or autoimmune disorders (e.g., rheumatoid arthritis, lupus)\n* Reports of recent benzodiazepine use (confirmed via rapid urine screening prior to each lab session)\n* Any medical conditions (e.g., significant cardiovascular disease) that the study physician feels would contraindicate participation in the lab stressors\n* Reported daily opiate use within the past 6 months, or use of any opioid analgesic medications within 3 days of study participation (confirmed through rapid urine screening prior to each lab session)\n* Pregnancy (females only, to avoid fetal drug exposure - pregnancy tests conducted prior to each lab session to confirm eligibility)\n* Prior allergic reaction\u002Fintolerance to oxycodone or its analogs",{"count":260,"type":22},[89],"The purpose of this study is to see how stress influences the effects of opioid pain medications often used to help relieve back pain. The study will help to learn more about how high stress levels could increase risk for pain medication misuse.",[687,30,688],"Opioid Use Disorder","Stress","2025-10-20",{"date":691,"type":36},"2025-10-21",{"date":693,"type":36},"2022-03-02",{"date":695,"type":22},"2026-07-31",{"name":697,"class":77},"Vanderbilt University Medical Center"]